CHICAGO — Corneal cross-linking should be considered in pediatric patients at diagnosis of clinically identifiable keratoconus, a speaker here said.
Even though FDA approval of the Avedro treatment system is indicated for progressive keratoconus in patients age 14 years or older, Erin D. Stahl, MD, said she treats children younger than 14 years at diagnosis.
Speaking at Pediatric Ophthalmology Subspecialty Day preceding the American Academy of Ophthalmology annual meeting, Stahl said, “When the diagnosis is made or considered, go on for the more sophisticated corneal analysis. And,
Uncategorized